JYNARQUE Drug Patent Profile
✉ Email this page to a colleague
When do Jynarque patents expire, and when can generic versions of Jynarque launch?
Jynarque is a drug marketed by Otsuka and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-six patent family members in twenty-four countries.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tolvaptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jynarque
A generic version of JYNARQUE was approved as tolvaptan by ALKEM LABS LTD on May 19th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JYNARQUE?
- What are the global sales for JYNARQUE?
- What is Average Wholesale Price for JYNARQUE?
Summary for JYNARQUE
| International Patents: | 86 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Patent Applications: | 1,174 |
| Drug Prices: | Drug price information for JYNARQUE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JYNARQUE |
| What excipients (inactive ingredients) are in JYNARQUE? | JYNARQUE excipients list |
| DailyMed Link: | JYNARQUE at DailyMed |
Pharmacology for JYNARQUE
| Drug Class | Vasopressin V2 Receptor Antagonist |
| Mechanism of Action | Vasopressin V2 Receptor Antagonists |
US Patents and Regulatory Information for JYNARQUE
JYNARQUE is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting JYNARQUE
Pharmaceutical solid preparation comprising benzazepines and production method thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Process for preparing benzazepine compounds or salts thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting JYNARQUE
INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-001 | Apr 23, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-003 | Apr 23, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-002 | Apr 23, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-004 | Apr 23, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JYNARQUE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-002 | Apr 23, 2018 | ⤷ Sign Up | ⤷ Sign Up |
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-005 | Apr 23, 2018 | ⤷ Sign Up | ⤷ Sign Up |
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-004 | Apr 23, 2018 | ⤷ Sign Up | ⤷ Sign Up |
| Otsuka | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-001 | Apr 23, 2018 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for JYNARQUE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Otsuka Pharmaceutical Netherlands B.V. | Jinarc | tolvaptan | EMEA/H/C/002788 Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. |
Authorised | no | no | no | 2015-05-27 | |
| Otsuka Pharmaceutical Netherlands B.V. | Samsca | tolvaptan | EMEA/H/C/000980 Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH)., |
Authorised | no | no | no | 2009-08-02 | |
| Accord Healthcare S.L.U. | Tolvaptan Accord | tolvaptan | EMEA/H/C/005961 Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). |
Authorised | yes | no | no | ||
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for JYNARQUE
When does loss-of-exclusivity occur for JYNARQUE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Austria
Patent: 96895
Estimated Expiration: ⤷ Sign Up
Patent: 44744
Estimated Expiration: ⤷ Sign Up
China
Patent: 1273017
Patent: Method of manufacturing benzoazepin compound or its salt
Estimated Expiration: ⤷ Sign Up
Patent: 1967107
Patent: Method of manufacturing benzoazepin compound or its salt
Estimated Expiration: ⤷ Sign Up
Patent: 2219741
Patent: Process for preparing benzazepine compounds or salts thereof
Estimated Expiration: ⤷ Sign Up
Patent: 2746229
Patent: Process for preparing benzazepine compounds or salts thereof
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 11788
Estimated Expiration: ⤷ Sign Up
Patent: 12496
Estimated Expiration: ⤷ Sign Up
Patent: 16082
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 19874
Estimated Expiration: ⤷ Sign Up
Patent: 51319
Estimated Expiration: ⤷ Sign Up
Patent: 61215
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 19874
Patent: PROCEDE DE PREPARATION DE COMPOSES DE BENZAZEPINE OU DE SELS DESDITS COMPOSES (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 51319
Patent: Procédés pour préparer des dérivés d' acide benzoïque (Process for preparing derivatives of benzoic acid)
Estimated Expiration: ⤷ Sign Up
Patent: 61215
Patent: Procédé de préparation de composés de benzazépine ou de leurs sels (Process for preparing benzazepine compounds or salts thereof)
Estimated Expiration: ⤷ Sign Up
Germany
Patent: 2006019882
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 24318
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 44932
Patent: PROCESS FOR PREPARING DERIVATIVES OF BENZOIC ACID
Estimated Expiration: ⤷ Sign Up
Patent: 45835
Patent: 製備苯並氮雜卓化合物或其鹽的方法 (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 48999
Patent: THE PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 72329
Patent: 製備苯並氮雜䓬化合物或其鹽的方法 (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9481
Patent: תהליך עבור הפקת תרכובות 2,3,4,5-טטרההידרו-h1-1-בנזאזפין או מלחים מזה ותרכובת נקייה מאוד המופקת על ידי תהליך האמור (Process for producing 2,3,4,5-tetrahydro-1h-1- benzazepine compounds or salts thereof and highly pure compounds produced by said process)
Estimated Expiration: ⤷ Sign Up
Patent: 7444
Patent: תהליך עבור תרכובות בנזאפין או מלחים מזה (Process for preparing benzazepine compounds or salts thereof)
Estimated Expiration: ⤷ Sign Up
Patent: 7445
Patent: תהליך עבור ייצור תרכובת חומצה בנזאוית (Process for producing a benzoic acid compound)
Estimated Expiration: ⤷ Sign Up
Patent: 7446
Patent: תכשיר רוקחי המכיל מרכיב פעיל מטוהר מאוד של 7- כלורו - 5 - הידרוקסי- 1- [2-מתיל-4-(2-מתילבנזואיל-אמינו)בנזואיל]-2, 3, 4, 5 - טטראהידרו- h 1 - 1 - בנזאזפין בעל טוהר של יותר מ - 99.5% או מלח שלו, או תכשיר רוקחות של מלח שלו (Pharmaceutical composition comprising as an active ingredient a highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl¬benzoyl¬amino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine having a purity of more than 99.5 %, or a salt thereof, or a pharmaceutically acceptable salt thereof)
Estimated Expiration: ⤷ Sign Up
Patent: 2396
Patent: תהליך הכנה תרכובת ל 4-(בנזואילאמינו) חומצה בנזואיק או מלחים שלהם (Process for preparing 4-(benzoylamino)benzoic acid compounds or salts thereof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 46587
Estimated Expiration: ⤷ Sign Up
Patent: 83172
Estimated Expiration: ⤷ Sign Up
Patent: 84164
Estimated Expiration: ⤷ Sign Up
Patent: 93083
Estimated Expiration: ⤷ Sign Up
Patent: 07091738
Patent: METHOD OF MANUFACTURING BENZOAZEPIN COMPOUND OR ITS SALT
Estimated Expiration: ⤷ Sign Up
Patent: 12176979
Patent: METHOD FOR PREPARING BENZAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 12197295
Patent: PROCESS FOR PREPARING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 12197296
Patent: PROCESS FOR PRODUCING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 14139203
Patent: METHOD OF PRODUCING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 14205699
Patent: ベンゾアゼピン化合物又はその塩の製造方法 (PRODUCTION METHOD OF BENZOAZEPINE COMPOUND OR SALT THEREOF)
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 19874
Estimated Expiration: ⤷ Sign Up
Patent: 51319
Estimated Expiration: ⤷ Sign Up
Patent: 61215
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 19874
Estimated Expiration: ⤷ Sign Up
Patent: 51319
Estimated Expiration: ⤷ Sign Up
Patent: 61215
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 19874
Estimated Expiration: ⤷ Sign Up
Patent: 51319
Estimated Expiration: ⤷ Sign Up
Patent: 61215
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1019363
Estimated Expiration: ⤷ Sign Up
Patent: 1077329
Estimated Expiration: ⤷ Sign Up
Patent: 1119732
Estimated Expiration: ⤷ Sign Up
Patent: 080039459
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 100132087
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 100133028
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 110029184
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 58217
Estimated Expiration: ⤷ Sign Up
Patent: 79153
Estimated Expiration: ⤷ Sign Up
Patent: 27794
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering JYNARQUE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 103989644 | Pharmaceutical solid preparation having benzoazepine and production method thereof | ⤷ Sign Up |
| European Patent Office | 0450097 | COMPOSES BENZOHETEROCYCLIQUES (BENZOHETEROCYCLIC COMPOUNDS) | ⤷ Sign Up |
| Israel | 217446 | תכשיר רוקחי המכיל מרכיב פעיל מטוהר מאוד של 7- כלורו - 5 - הידרוקסי- 1- [2-מתיל-4-(2-מתילבנזואיל-אמינו)בנזואיל]-2, 3, 4, 5 - טטראהידרו- h 1 - 1 - בנזאזפין בעל טוהר של יותר מ - 99.5% או מלח שלו, או תכשיר רוקחות של מלח שלו (Pharmaceutical composition comprising as an active ingredient a highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl¬benzoyl¬amino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine having a purity of more than 99.5 %, or a salt thereof, or a pharmaceutically acceptable salt thereof) | ⤷ Sign Up |
| Japan | 2905909 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JYNARQUE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0450097 | C300408 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803 |
| 0450097 | CA 2009 00031 | Denmark | ⤷ Sign Up | |
| 0450097 | 09C0049 | France | ⤷ Sign Up | PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803 |
| 0450097 | 300408 | Netherlands | ⤷ Sign Up | 300408, 20101018, EXPIRES: 20151017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
